Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans., 71351 [2011-29726]

Download as PDF Federal Register / Vol. 76, No. 222 / Thursday, November 17, 2011 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, December 12, 2011, 1 p.m. to December 12, 2011, 3 p.m., (Telephone Conference Call), National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the Federal Register on November 3, 2011, 76 FR 68200–68201. The meeting has been changed to a Video Assisted Meeting and will be held on December 14, 2011. The meeting location and time remain the same. The meeting is closed to the public. Dated: November 9, 2011. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. Natcher Building, Room 3AN18J, Bethesda, MD 20892, (301) 594–2773, laffanjo@nigms.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS) Dated: November 9, 2011. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2011–29727 Filed 11–16–11; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans. [FR Doc. 2011–29728 Filed 11–16–11; 8:45 am] BILLING CODE 4140–01–P National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the invention embodied in U.S. Patent 6,630,507, entitled ‘‘Cannabinoids as antioxidants and neuroprotectants’’ and PCT Application Serial No. PCT/US99/08769 and foreign equivalents thereof, entitled ‘‘Cannabinoids as antioxidants and neuroprotectants’’ [HHS Ref. No. E– 287–1997/2] to KannaLife Sciences Inc., which has offices in New York, U.S. This patent and its foreign counterparts have been assigned to the Government of the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to: SUMMARY: National Institute of General Medical Sciences; Notice of Closed Meeting jlentini on DSK4TPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel, Review of MARC Grant Applications. Date: December 5, 2011. Time: 1 p.m. to3 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Natcher Building, 45 Center Drive, Room 3AN18, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: John J. Laffan, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, VerDate Mar<15>2010 17:25 Nov 16, 2011 Jkt 226001 The development and sale of cannabinoid(s) and cannabidiol(s) based therapeutics as antioxidants and neuroprotectants for use and delivery in humans, for the treatment of hepatic encephalopathy, as claimed in the Licensed Patent Rights. Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before December 19, 2011 will be considered. DATES: PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 71351 Requests for copy of the patent, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Betty B. Tong, Ph.D., Senior Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 594–6565; Facsimile: (301) 402–0220; Email: tongb@mail.nih.gov. SUPPLEMENTARY INFORMATION: The technology describes pharmaceutical compositions of cannabinoids that are useful as tissue protectants, such as neuroprotectants and cardioprotectants. The cannabinoids compounds may be used, for example, in the treatment of acute ischemic neurological insults or chronic neurodegenerative diseases. Nonpsychoactive cannabinoids, such as Cannabidiol (CBD), are particularly advantageous since they avoid toxicity that is encountered with psychoactive cannabinoids at high doses. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective exclusive license may be granted unless within thirty (30) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. ADDRESSES: Dated: November 10, 2011. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2011–29726 Filed 11–16–11; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Proposed Collection; Comment Request In compliance with Section 3506(c)(2)(A) of the Paperwork E:\FR\FM\17NON1.SGM 17NON1

Agencies

[Federal Register Volume 76, Number 222 (Thursday, November 17, 2011)]
[Notices]
[Page 71351]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-29726]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Development of 
Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic 
Encephalopathy in Humans.

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR part 404.7(a)(1)(i), that the National Institutes of Health, 
Department of Health and Human Services, is contemplating the grant of 
an exclusive patent license to practice the invention embodied in U.S. 
Patent 6,630,507, entitled ``Cannabinoids as antioxidants and 
neuroprotectants'' and PCT Application Serial No. PCT/US99/08769 and 
foreign equivalents thereof, entitled ``Cannabinoids as antioxidants 
and neuroprotectants'' [HHS Ref. No. E-287-1997/2] to KannaLife 
Sciences Inc., which has offices in New York, U.S. This patent and its 
foreign counterparts have been assigned to the Government of the United 
States of America.
    The prospective exclusive license territory may be worldwide, and 
the field of use may be limited to:

    The development and sale of cannabinoid(s) and cannabidiol(s) 
based therapeutics as antioxidants and neuroprotectants for use and 
delivery in humans, for the treatment of hepatic encephalopathy, as 
claimed in the Licensed Patent Rights.


DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
December 19, 2011 will be considered.

ADDRESSES: Requests for copy of the patent, inquiries, comments, and 
other materials relating to the contemplated exclusive license should 
be directed to: Betty B. Tong, Ph.D., Senior Licensing and Patenting 
Manager, Office of Technology Transfer, National Institutes of Health, 
6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 594-6565; Facsimile: (301) 402-0220; Email: 
tongb@mail.nih.gov.

SUPPLEMENTARY INFORMATION: The technology describes pharmaceutical 
compositions of cannabinoids that are useful as tissue protectants, 
such as neuroprotectants and cardioprotectants. The cannabinoids 
compounds may be used, for example, in the treatment of acute ischemic 
neurological insults or chronic neurodegenerative diseases. 
Nonpsychoactive cannabinoids, such as Cannabidiol (CBD), are 
particularly advantageous since they avoid toxicity that is encountered 
with psychoactive cannabinoids at high doses.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404.7. The prospective exclusive license may be granted unless within 
thirty (30) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR part 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: November 10, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-29726 Filed 11-16-11; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.